Neuromuscular Disease Conferences | Europe | Asia | Middle East | Canada | Japan | Australia | USA

Neuromuscular Disease

Neuromuscular disease encompasses various disease and disorders which affects the nerves that control muscle function and neuromuscular system. Neuromuscular disorders can generate difficulties with the nerves carrying information back to the brain, nerves that control voluntary muscles, and transmission between nerve and muscles. These disorders can make the muscles weak and may lose functioning as well.

Some signs and symptoms of neurological disorders or neurological disease are muscle loss, muscle weakness, double vision, trouble breathing and swallowing, numbness, balancing problem, and movement issues. Signs and symptoms for some of the neurological disorders can be visible in the infant stage as well. In general, there is no cure for these disorders. But prevention, prognosis, and management of these diseases vary according to the severity and types of these disorders.

Sub-tracks:

Spinal muscular atrophy
Myasthenia gravis
Researches on Neuromuscular disease and disorders
Myositis, including polymyositis and dermatomyositis
Myopathy
Charcot-Marie-Tooth disease
Amyotrophic lateral sclerosis (ALS)
Neuromuscular Disorders
Multiple sclerosis
Neuromuscular disease causes and risk factors
Autoimmune disorders
Peripheral neuropathy
Muscular dystrophy

Market Analysis: The Neuromuscular Disease Therapeutics Market is set for substantial growth between 2025 and 2030, with various reports projecting robust Compound Annual Growth Rates (CAGRs). General market forecasts hover around 11-15%, with MarketResearch.com predicting a 15.0% CAGR and Technavio a 14.6% CAGR. Specialized segments anticipate even higher growth, such as the Duchenne Muscular Dystrophy (DMD) Treatment Market at 19.13% (Mordor Intelligence) and the market for Zilbrysq (zilucoplan) for generalized myasthenia gravis, which could reach an impressive 28.39% CAGR (Grand View Research). This vigorous expansion is primarily driven by increasing diagnosis rates, breakthroughs in gene therapies and other novel treatments, a strong pipeline of developing drugs, and supportive regulatory environments.

Tracks